Paper Details

  1. Home
  2. Paper Details

Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.

Author: BhogalJaskaran S, CarapellucciSarah, IbrahimSamir, JurutkaPeter W, LealAna S, LibyKaren T, MarshallPamela A, RabanSan, ShahaniPritika H, SpornMichael B, WagnerCarl E, ZhangDi

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluates novel pyrimidinyl analogues of bexarotene and LG100268, two known chemopreventive rexinoids, as potential cancer prevention agents. These analogues demonstrate improved efficacy and safety profiles compared to the existing rexinoids, with promising immunomodulatory and anti-inflammatory activities.
Paper Details　
Original Abstract of the Article :
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the search for new and better rexinoids. Here we report...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1940-6207.CAPR-18-0317

データ提供：米国国立医学図書館（NLM）

Rexinoids: A New Oasis in the Desert of Cancer Prevention

The desert of cancer prevention is vast and complex, and researchers are constantly seeking new strategies to combat this disease. Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing various types of cancer. However, the only clinically approved rexinoid, bexarotene, has limitations in efficacy and side effects. This research embarks on a quest for new and better rexinoids, focusing on novel pyrimidinyl (Py) analogues of bexarotene and LG100268. The researchers seek to create more effective and safer rexinoids, potentially leading to a new era of cancer prevention.

A New Oasis of Hope

This research demonstrates that these novel pyrimidinyl derivatives are more effective than bexarotene in preventing lung carcinogenesis. Furthermore, they exhibit an improved safety profile, causing less elevation of plasma triglyceride levels and even reducing plasma cholesterol levels compared to their predecessors. This discovery could potentially lead to a new generation of rexinoids with greater efficacy and fewer side effects, providing a valuable tool in the fight against cancer.

A Brighter Future for Cancer Prevention

The research's focus on immunomodulatory and anti-inflammatory activities of rexinoids opens up new avenues for cancer prevention. By targeting the immune system and reducing inflammation, these novel rexinoids could potentially disrupt the development of cancer. This research offers a glimmer of hope for a future where cancer prevention strategies are more effective and less burdensome for patients.

Dr.Camel's Conclusion

The desert of cancer prevention can be a challenging terrain, but this research offers a promising oasis. These novel pyrimidinyl rexinoids represent a significant step forward in the fight against cancer. Their enhanced efficacy and improved safety profile provide a ray of hope for a future where cancer prevention is more accessible and effective. This research is a reminder that even in the vast desert of cancer research, there are always new discoveries waiting to be unearthed.

Date :
  1. Date Completed 2020-07-13
  2. Date Revised 2020-07-13
Further Info :

Pubmed ID

30760500

DOI: Digital Object Identifier

10.1158/1940-6207.CAPR-18-0317

Related Literature

Article Analysis
・Side Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.